Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

LONDON, GREATER LONDON, UNITED KINGDOM, February 7, 2025 /EINPresswire / -- The novolog or novomix or novorapid market has seen a robust Compound Annual Growth Rate CAGR in recent years and is ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC ...

Novo Nordisk’s CEO toasted the company’s record-breaking profitability and earnings on Wednesday morning as the group behind Ozempic and Wegovy put on a brave face about its ability to fight ...

Ozempic has become emblematic of the explosive enthusiasm for GLP-1 medications in the U.S. Danish pharmaceutical giant Novo ... Nordisk is the manufacturer of Ozemipc; its diabetes medication ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

Novo Nordisk reported $40.5 billion in sales for 2024, surpassing Wall Street’s expectations. Its success was driven by its two GLP-1 drugs, Ozempic and Wegovy. The company is in a race with ...